65 related articles for article (PubMed ID: 9820831)
1. Comorbid survival among elderly male participants of the Canada health survey: relevance to prostate cancer screening and treatment.
Eapen L; Villeneuve PJ; Levy IG; Morrison HI
Chronic Dis Can; 1998; 19(3):84-90. PubMed ID: 9820831
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
3. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
4. Predictors of prostate cancer screening among health fair participants.
Chiu BC; Anderson JR; Corbin D
Public Health; 2005 Aug; 119(8):686-93. PubMed ID: 15949522
[TBL] [Abstract][Full Text] [Related]
5. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
Welch HG; Schwartz LM; Woloshin S
J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen test use reported in the 2000 National Health Interview Survey.
Ross LE; Coates RJ; Breen N; Uhler RJ; Potosky AL; Blackman D
Prev Med; 2004 Jun; 38(6):732-44. PubMed ID: 15193893
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer incidence and survival in relation to education (United States).
Steenland K; Rodriguez C; Mondul A; Calle EE; Thun M
Cancer Causes Control; 2004 Nov; 15(9):939-45. PubMed ID: 15577296
[TBL] [Abstract][Full Text] [Related]
9. Behavioral associations between prostate and colon cancer screening.
Carlos RC; Underwood W; Fendrick AM; Bernstein SJ
J Am Coll Surg; 2005 Feb; 200(2):216-23. PubMed ID: 15664097
[TBL] [Abstract][Full Text] [Related]
10. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
12. Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men.
Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR
Cancer Causes Control; 2008 Feb; 19(1):25-31. PubMed ID: 17906959
[TBL] [Abstract][Full Text] [Related]
13. Glaucoma and survival: the National Health Interview Survey 1986-1994.
Lee DJ; Gómez-Marín O; Lam BL; Zheng DD
Ophthalmology; 2003 Aug; 110(8):1476-83. PubMed ID: 12917160
[TBL] [Abstract][Full Text] [Related]
14. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
Ulmert D; Serio AM; O'Brien MF; Becker C; Eastham JA; Scardino PT; Björk T; Berglund G; Vickers AJ; Lilja H
J Clin Oncol; 2008 Feb; 26(6):835-41. PubMed ID: 18281654
[TBL] [Abstract][Full Text] [Related]
15. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
16. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity.
Adolfsson J; Tribukait B; Levitt S
Eur Urol; 2007 Oct; 52(4):1028-35. PubMed ID: 17467883
[TBL] [Abstract][Full Text] [Related]
17. Demographics and health-related factors of men receiving prostate-specific antigen screening in Utah.
Merrill RM
Prev Med; 2001 Dec; 33(6):646-52. PubMed ID: 11716662
[TBL] [Abstract][Full Text] [Related]
18. Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer.
Birim O; Kappetein AP; Bogers AJ
Eur J Cardiothorac Surg; 2005 Nov; 28(5):759-62. PubMed ID: 16157485
[TBL] [Abstract][Full Text] [Related]
19. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
[TBL] [Abstract][Full Text] [Related]
20. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB
Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
